SPORE in Brain Cancer

脑癌中的孢子

• 批准号: 7921427
• 负责人: W K ALFRED Yung
• 金额: $ 230万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7921427
• 关键词: SPORE; Brain; Cancer

The objective of The University of Texas M. D. Anderson Cancer Center (UTMDACC) SPORE in Brain Cancer is to develop a robust translational research program with an emphasis on innovative treatments based on combinations of agents, molecularly-based diagnosis, and therapy monitoring, through which significant impact on the care of patients with malignant brain tumors will be achieved. UTMDACC has established the elimination of brain tumors as a priority and has made significant investments in this goal through establishment of a Brain Tumor Center and a Multidisciplinary Research Program to support training and research across several departmental boundaries, including neuro-oncology, neuro-surgery, neuro-pathology, diagnostic imaging, radiation oncology, epidemiology, molecular therapeutics, molecular genetics, molecular biology, pediatrics, and statistics. With this support, we have successfully organized an efficient and productive infrastructure that forms the basis for this SPORE. The translational research in this application is based on recent insights into the molecular basis of brain tumors and aims to translate these findings into innovative approaches to improve molecular diagnosis so that patients receive the therapy most likely to be benefit them, permit early evaluation of response to targeted treatment, and establish new and effective treatments based on oncolytic viruses and small molecule signal transduction inhibitors. The focus of the four Projects is described below: Project 1: Test a targeted oncolytic adenovirus, Delta-24-RGD in the clinic, and improve it by combining it with temozolomide and by delivery with mesenchymal stem cells. Project 2: Test PI3K inhibitor PX-866 in the clinic and develop rational combination therapies based on it. Project 3: Develop a molecular biomarker panel capable of identifying patients not likely to benefit from standard therapy, test it in the RTOG-0525 clinical trial with over 800 patients, and identify novel targets in the treatment of resistant tumors to support new therapy development. Project 4: Explore genetic predictors of neurocognitive and clinical outcome in glioblastoma patients. Five Cores (Administrative, Pathology and Tissue Procurement, Biostatistics, Clinical and Animal) will support the Projects, Career Development Program, and Developmental Research Program. It is imperative that we aggressively undertake translational research, as is embodied in this proposal to develop more effective approaches for patients with brain cancer; there are no effective treatment approaches for this patient population, and this SPORE guarantees that all of the resources of the UTMDACC Brain Tumor Research Program, as well as the considerable resources of the entire institution, will be brought to bear on this important public health problem.

德克萨斯大学M. D.安德森癌症中心（UTMDACC）的脑癌SPORE项目旨在开发一个强大的转化研究项目，重点是基于药物组合的创新治疗、基于分子的诊断和治疗监测，通过这些项目将对恶性脑肿瘤患者的护理产生重大影响。UTMDACC已将消除脑肿瘤确定为优先事项，并通过建立脑肿瘤中心和多学科研究计划为这一目标进行了大量投资，以支持跨几个部门的培训和研究，包括神经肿瘤学，神经外科学，神经病理学，诊断成像学，放射肿瘤学，流行病学，分子治疗学，分子遗传学，分子生物学，儿科学，和统计数据。在这种支持下，我们成功地组织了一个高效和富有成效的基础设施，构成了这个SPORE的基础。本申请中的转化研究基于对脑肿瘤分子基础的最新见解，旨在将这些发现转化为创新方法，以改善分子诊断，使患者接受最有可能使其受益的治疗，允许早期评估对靶向治疗的反应，并建立基于溶瘤病毒和小分子信号转导抑制剂的新的有效治疗方法。这四个项目的重点如下： 项目一：在临床上测试一种靶向溶瘤腺病毒Delta-24-RGD，并通过与替莫唑胺联合使用和与间充质干细胞一起输送来改善它。 项目二：PI 3 K抑制剂PX-866的临床试验，并在此基础上开发合理的联合治疗方案。 项目三：开发一个能够识别不太可能从标准治疗中获益的患者的分子生物标志物组，在RTOG-0525临床试验中对800多名患者进行测试，并确定治疗耐药肿瘤的新靶点，以支持新疗法的开发。 项目4：探索胶质母细胞瘤患者神经认知和临床结局的遗传预测因子。 五个核心（行政，病理学和组织采购，生物统计学，临床和动物）将支持项目，职业发展计划和发展研究计划。我们必须积极开展转化研究，这体现在为脑癌患者开发更有效方法的建议中;对于这一患者群体没有有效的治疗方法，该SPORE保证UTMDACC脑肿瘤研究计划的所有资源，以及整个机构的大量资源，将对这一重要的公共卫生问题产生影响。